Last reviewed · How we verify
Umbilical Cord-derived Wharton's Jelly
At a glance
| Generic name | Umbilical Cord-derived Wharton's Jelly |
|---|---|
| Sponsor | BioIntegrate |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease (PHASE1)
- Guttmann NeuroRecovery - Viability, Safety, and Efficacy of Intrathecal Wharton's Jelly Mesenchymal Stem Cells and Transcutaneous Spinal Cord Stimulation in Chronic Spinal Cord Injury Rehabilitation (PHASE1, PHASE2)
- MSCs for Prevention of MI-induced HF (PHASE3)
- Effects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury. (PHASE2)
- Preliminary Safety and Efficacy Study of Extracellular Vesicle Infusion in the Intervention of Age-related Phenotypes With Impaired Glucose Tolerance. (NA)
- Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19 (EARLY_PHASE1)
- Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision (PHASE3)
- Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Umbilical Cord-derived Wharton's Jelly CI brief — competitive landscape report
- Umbilical Cord-derived Wharton's Jelly updates RSS · CI watch RSS
- BioIntegrate portfolio CI